A Retrospective Study of Canine Pancytopenia

Douglas J. Weiss, Oral A. Evanson, Jane E Sykes

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

To better define the incidence and causes of canine pancytopenia, we retrospectively evaluated the results of complete blood counts submitted to the University of Minnesota Veterinary Teaching Hospital during a 1-year period. Pancytopenia was defined as packed cell volume < 36%, total leukocyte count < 6,000/μL or total segmented neutrophil count < 3,000/μL, and platelet count < 200,000/μL. Of 4,560 complete blood counts, 110 (2.4%) samples from 51 dogs met the criteria for pancytopenia. Eleven different disease processes were identified. These included chemotherapy-associated pancytopenia (n = 22), parvovirus infection (n = 5), malignant histiocytosis (n = 5), idiopathic aplastic anemia (n = 3), sepsis (n = 3), myelodysplastic syndrome (n = 3), immune-mediated hematologic disease (n = 3), lymphoblastic leukemia (n = 2), ehrlichiosis (n = 2), estrogen toxicity (n = 2), and multiple myeloma (n = 1). Malignant histiocytosis and idiopathic aplastic anemia occurred more frequently than was expected. Doxorubicin was the chemotherapeutic agent associated with pancytopenia. Hematologic recovery and patient survival time varied with the cause of pancytopenia; therefore, a specific diagnosis was essential for establishing prognosis. Differentiation among causes of pancytopenia requires a systematic approach that includes elimination of infectious and drug-induced causes, and examination of bone marrow aspiration and core biopsy specimens.

Original languageEnglish (US)
Pages (from-to)83-88
Number of pages6
JournalVeterinary Clinical Pathology
Volume28
Issue number3
StatePublished - 1999
Externally publishedYes

Fingerprint

histiocytosis
Pancytopenia
retrospective studies
anemia
Canidae
Blood
Retrospective Studies
hematologic diseases
ehrlichiosis
lymphocytic leukemia
sepsis (infection)
Protoparvovirus
myeloma
doxorubicin
Chemotherapy
blood platelet count
Biopsy
dogs
blood
Platelets

Keywords

  • Aplasia
  • Bone marrow
  • Canine
  • Dysplasia
  • Pancytopenia

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • veterinary(all)

Cite this

A Retrospective Study of Canine Pancytopenia. / Weiss, Douglas J.; Evanson, Oral A.; Sykes, Jane E.

In: Veterinary Clinical Pathology, Vol. 28, No. 3, 1999, p. 83-88.

Research output: Contribution to journalArticle

Weiss, DJ, Evanson, OA & Sykes, JE 1999, 'A Retrospective Study of Canine Pancytopenia', Veterinary Clinical Pathology, vol. 28, no. 3, pp. 83-88.
Weiss, Douglas J. ; Evanson, Oral A. ; Sykes, Jane E. / A Retrospective Study of Canine Pancytopenia. In: Veterinary Clinical Pathology. 1999 ; Vol. 28, No. 3. pp. 83-88.
@article{b8ac1bc409034e078f0088b333f9301c,
title = "A Retrospective Study of Canine Pancytopenia",
abstract = "To better define the incidence and causes of canine pancytopenia, we retrospectively evaluated the results of complete blood counts submitted to the University of Minnesota Veterinary Teaching Hospital during a 1-year period. Pancytopenia was defined as packed cell volume < 36{\%}, total leukocyte count < 6,000/μL or total segmented neutrophil count < 3,000/μL, and platelet count < 200,000/μL. Of 4,560 complete blood counts, 110 (2.4{\%}) samples from 51 dogs met the criteria for pancytopenia. Eleven different disease processes were identified. These included chemotherapy-associated pancytopenia (n = 22), parvovirus infection (n = 5), malignant histiocytosis (n = 5), idiopathic aplastic anemia (n = 3), sepsis (n = 3), myelodysplastic syndrome (n = 3), immune-mediated hematologic disease (n = 3), lymphoblastic leukemia (n = 2), ehrlichiosis (n = 2), estrogen toxicity (n = 2), and multiple myeloma (n = 1). Malignant histiocytosis and idiopathic aplastic anemia occurred more frequently than was expected. Doxorubicin was the chemotherapeutic agent associated with pancytopenia. Hematologic recovery and patient survival time varied with the cause of pancytopenia; therefore, a specific diagnosis was essential for establishing prognosis. Differentiation among causes of pancytopenia requires a systematic approach that includes elimination of infectious and drug-induced causes, and examination of bone marrow aspiration and core biopsy specimens.",
keywords = "Aplasia, Bone marrow, Canine, Dysplasia, Pancytopenia",
author = "Weiss, {Douglas J.} and Evanson, {Oral A.} and Sykes, {Jane E}",
year = "1999",
language = "English (US)",
volume = "28",
pages = "83--88",
journal = "Veterinary Clinical Pathology",
issn = "0275-6382",
publisher = "American Society for Veterinary Clinical Pathology",
number = "3",

}

TY - JOUR

T1 - A Retrospective Study of Canine Pancytopenia

AU - Weiss, Douglas J.

AU - Evanson, Oral A.

AU - Sykes, Jane E

PY - 1999

Y1 - 1999

N2 - To better define the incidence and causes of canine pancytopenia, we retrospectively evaluated the results of complete blood counts submitted to the University of Minnesota Veterinary Teaching Hospital during a 1-year period. Pancytopenia was defined as packed cell volume < 36%, total leukocyte count < 6,000/μL or total segmented neutrophil count < 3,000/μL, and platelet count < 200,000/μL. Of 4,560 complete blood counts, 110 (2.4%) samples from 51 dogs met the criteria for pancytopenia. Eleven different disease processes were identified. These included chemotherapy-associated pancytopenia (n = 22), parvovirus infection (n = 5), malignant histiocytosis (n = 5), idiopathic aplastic anemia (n = 3), sepsis (n = 3), myelodysplastic syndrome (n = 3), immune-mediated hematologic disease (n = 3), lymphoblastic leukemia (n = 2), ehrlichiosis (n = 2), estrogen toxicity (n = 2), and multiple myeloma (n = 1). Malignant histiocytosis and idiopathic aplastic anemia occurred more frequently than was expected. Doxorubicin was the chemotherapeutic agent associated with pancytopenia. Hematologic recovery and patient survival time varied with the cause of pancytopenia; therefore, a specific diagnosis was essential for establishing prognosis. Differentiation among causes of pancytopenia requires a systematic approach that includes elimination of infectious and drug-induced causes, and examination of bone marrow aspiration and core biopsy specimens.

AB - To better define the incidence and causes of canine pancytopenia, we retrospectively evaluated the results of complete blood counts submitted to the University of Minnesota Veterinary Teaching Hospital during a 1-year period. Pancytopenia was defined as packed cell volume < 36%, total leukocyte count < 6,000/μL or total segmented neutrophil count < 3,000/μL, and platelet count < 200,000/μL. Of 4,560 complete blood counts, 110 (2.4%) samples from 51 dogs met the criteria for pancytopenia. Eleven different disease processes were identified. These included chemotherapy-associated pancytopenia (n = 22), parvovirus infection (n = 5), malignant histiocytosis (n = 5), idiopathic aplastic anemia (n = 3), sepsis (n = 3), myelodysplastic syndrome (n = 3), immune-mediated hematologic disease (n = 3), lymphoblastic leukemia (n = 2), ehrlichiosis (n = 2), estrogen toxicity (n = 2), and multiple myeloma (n = 1). Malignant histiocytosis and idiopathic aplastic anemia occurred more frequently than was expected. Doxorubicin was the chemotherapeutic agent associated with pancytopenia. Hematologic recovery and patient survival time varied with the cause of pancytopenia; therefore, a specific diagnosis was essential for establishing prognosis. Differentiation among causes of pancytopenia requires a systematic approach that includes elimination of infectious and drug-induced causes, and examination of bone marrow aspiration and core biopsy specimens.

KW - Aplasia

KW - Bone marrow

KW - Canine

KW - Dysplasia

KW - Pancytopenia

UR - http://www.scopus.com/inward/record.url?scp=0033435936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033435936&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033435936

VL - 28

SP - 83

EP - 88

JO - Veterinary Clinical Pathology

JF - Veterinary Clinical Pathology

SN - 0275-6382

IS - 3

ER -